Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

High materiality8/10

BrainStorm presses NurOwn Phase 3b with FDA SPA and leadership change

Aug 14, 2026, 4:06 PM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Near-term liquidity concerns weigh on sentiment despite positive regulatory progress and leadership changes; need for additional fundraising could pressure shares absent meaningful clinical progress or financing clarity.

AI summary

What happened, with direct paths to the underlying reporting

BrainStorm disclosed a near-term liquidity challenge with $0.2 million in cash as of 6/30/2026, while highlighting regulatory progress for NurOwn's Phase 3b ENDURANCE study under an FDA Special Protocol Assessment. The company appointed Peter Pitts as Executive Chairman to drive regulatory, operations, and capital-market initiatives, and disclosed a $0.4 million private placement in May 2026, bringing H1 2026 raises to about $2.4 million. Key catalysts include the ENDURANCE readout potential and SPA-backed ALS development, offset by persistent liquidity risk.

Q2 2026 cash $0.2M; net loss $3.9M; EPS $(0.35).
R&D $1.0M; G&A $2.7M; burn persists year-over-year.
Peter Pitts named Executive Chairman; ENDURANCE Phase 3b readied under SPA with FDA.
ENDURANCE targets ~200 ALS patients in two 24-week parts; primary endpoint ALSFRS-R.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.